Less controversial alternative to ivermectin could be Regen-Cov
Clinical trial provides the clearest evidence of the therapy’s effectiveness among hospitalised patients
Regeneron Pharmaceuticals’s Covid-19 antibody cocktail reduces deaths in hospitalised patients who have not mounted their own antibody response, a large British study published on Wednesday found.
The therapy, Regen-Cov, has been granted emergency use authorisation for people with mild to moderate Covid-19 in the US, but results from the Recovery trial provide the clearest evidence of its effectiveness among hospitalised patients.
It found that the antibody therapy reduced by a fifth the 28-day mortality of people admitted to hospital with Covid-19 whose immune systems had not mounted an antibody response, known as seronegative...